tetano
Editor, Senior Moderator
ERJ Open Res
. 2022 Apr 11;8(2):00004-2022.
doi: 10.1183/23120541.00004-2022. eCollection 2022 Apr.
Prospective longitudinal evaluation of hospitalised COVID-19 survivors 3 and 12 months after discharge
Natalie Lorent[SUP] 1 2 [/SUP], Yannick Vande Weygaerde[SUP] 3 2 [/SUP], Eveline Claeys[SUP] 1 2 [/SUP], Ipek Guler Caamano Fajardo[SUP] 4 [/SUP], Nicolas De Vos[SUP] 5 [/SUP], Walter De Wever[SUP] 6 [/SUP], Bihiyga Salhi[SUP] 3 [/SUP], Iwein Gyselinck[SUP] 1 [/SUP], Cedric Bosteels[SUP] 3 [/SUP], Bart N Lambrecht[SUP] 3 7 8 9 [/SUP], Stephanie Everaerts[SUP] 1 [/SUP], Sven Verschraegen[SUP] 3 [/SUP], Christophe Schepers[SUP] 6 [/SUP], Heleen Demeyer[SUP] 10 11 [/SUP], Arne Heyns[SUP] 12 [/SUP], Pieter Depuydt[SUP] 8 9 [/SUP], Sandra Oeyen[SUP] 8 9 [/SUP], Pascal Van Bleyenbergh[SUP] 1 [/SUP], Laurent Godinas[SUP] 1 [/SUP], Lieven Dupont[SUP] 1 13 [/SUP], Greet Hermans[SUP] 14 15 [/SUP], Eric Derom[SUP] 3 9 [/SUP], Rik Gosselink[SUP] 7 [/SUP], Wim Janssens[SUP] 1 13 [/SUP], Eva Van Braeckel[SUP] 3 9 [/SUP]
Affiliations
Abstract
Background: Long-term outcome data of coronavirus disease 2019 (COVID-19) survivors are needed to understand their recovery trajectory and additional care needs.
Methods: A prospective observational multicentre cohort study was carried out of adults hospitalised with COVID-19 from March through May 2020. Workup at 3 and 12 months following admission consisted of clinical review, pulmonary function testing, 6-min walk distance (6MWD), muscle strength, chest computed tomography (CT) and quality of life questionnaires. We evaluated factors correlating with recovery by linear mixed effects modelling.
Results: Of 695 patients admitted, 299 and 226 returned at 3 and 12 months, respectively (median age 59 years, 69% male, 31% severe disease). About half and a third of the patients reported fatigue, dyspnoea and/or cognitive impairment at 3 and 12 months, respectively. Reduced 6MWD and quadriceps strength were present in 20% and 60% at 3 months versus 7% and 30% at 12 months. A high anxiety score and body mass index correlated with poor functional recovery. At 3 months, diffusing capacity for carbon monoxide (D [SUB]LCO[/SUB]) and total lung capacity were below the lower limit of normal in 35% and 18%, decreasing to 21% and 16% at 12 months; predictors of poor D [SUB]LCO[/SUB] recovery were female sex, pre-existing lung disease, smoking and disease severity. Chest CT improved over time; 10% presented non-progressive fibrotic changes at 1 year.
Conclusion: Many COVID-19 survivors, especially those with severe disease, experienced limitations at 3 months. At 1 year, the majority showed improvement to almost complete recovery. To identify additional care or rehabilitation needs, we recommend a timely multidisciplinary follow-up visit following COVID-19 admission.
. 2022 Apr 11;8(2):00004-2022.
doi: 10.1183/23120541.00004-2022. eCollection 2022 Apr.
Prospective longitudinal evaluation of hospitalised COVID-19 survivors 3 and 12 months after discharge
Natalie Lorent[SUP] 1 2 [/SUP], Yannick Vande Weygaerde[SUP] 3 2 [/SUP], Eveline Claeys[SUP] 1 2 [/SUP], Ipek Guler Caamano Fajardo[SUP] 4 [/SUP], Nicolas De Vos[SUP] 5 [/SUP], Walter De Wever[SUP] 6 [/SUP], Bihiyga Salhi[SUP] 3 [/SUP], Iwein Gyselinck[SUP] 1 [/SUP], Cedric Bosteels[SUP] 3 [/SUP], Bart N Lambrecht[SUP] 3 7 8 9 [/SUP], Stephanie Everaerts[SUP] 1 [/SUP], Sven Verschraegen[SUP] 3 [/SUP], Christophe Schepers[SUP] 6 [/SUP], Heleen Demeyer[SUP] 10 11 [/SUP], Arne Heyns[SUP] 12 [/SUP], Pieter Depuydt[SUP] 8 9 [/SUP], Sandra Oeyen[SUP] 8 9 [/SUP], Pascal Van Bleyenbergh[SUP] 1 [/SUP], Laurent Godinas[SUP] 1 [/SUP], Lieven Dupont[SUP] 1 13 [/SUP], Greet Hermans[SUP] 14 15 [/SUP], Eric Derom[SUP] 3 9 [/SUP], Rik Gosselink[SUP] 7 [/SUP], Wim Janssens[SUP] 1 13 [/SUP], Eva Van Braeckel[SUP] 3 9 [/SUP]
Affiliations
- PMID: 35415186
- PMCID: PMC8994962
- DOI: 10.1183/23120541.00004-2022
Abstract
Background: Long-term outcome data of coronavirus disease 2019 (COVID-19) survivors are needed to understand their recovery trajectory and additional care needs.
Methods: A prospective observational multicentre cohort study was carried out of adults hospitalised with COVID-19 from March through May 2020. Workup at 3 and 12 months following admission consisted of clinical review, pulmonary function testing, 6-min walk distance (6MWD), muscle strength, chest computed tomography (CT) and quality of life questionnaires. We evaluated factors correlating with recovery by linear mixed effects modelling.
Results: Of 695 patients admitted, 299 and 226 returned at 3 and 12 months, respectively (median age 59 years, 69% male, 31% severe disease). About half and a third of the patients reported fatigue, dyspnoea and/or cognitive impairment at 3 and 12 months, respectively. Reduced 6MWD and quadriceps strength were present in 20% and 60% at 3 months versus 7% and 30% at 12 months. A high anxiety score and body mass index correlated with poor functional recovery. At 3 months, diffusing capacity for carbon monoxide (D [SUB]LCO[/SUB]) and total lung capacity were below the lower limit of normal in 35% and 18%, decreasing to 21% and 16% at 12 months; predictors of poor D [SUB]LCO[/SUB] recovery were female sex, pre-existing lung disease, smoking and disease severity. Chest CT improved over time; 10% presented non-progressive fibrotic changes at 1 year.
Conclusion: Many COVID-19 survivors, especially those with severe disease, experienced limitations at 3 months. At 1 year, the majority showed improvement to almost complete recovery. To identify additional care or rehabilitation needs, we recommend a timely multidisciplinary follow-up visit following COVID-19 admission.